
|Articles|June 2, 2014
A Phase I Study of the CSF1R Kinase Inhibitor PLX3397 for PVNS
Author(s)William D. Tap, MD
William D. Tap, MD, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).
Advertisement
William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















